Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics (Nasdaq: CMMB) said CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:00 am ET.

Rhea-AI Summary

Chemomab Therapeutics (Nasdaq: CMMB) said CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:00 am ET.

The corporate presentation will be webcast live and available on the company's investor relations website for 90 days; management will also hold one-on-one investor meetings.

Market Context

This announcement highlights Chemomab’s continued investor outreach, with management presenting at t...

Analysis

This announcement highlights Chemomab’s continued investor outreach, with management presenting at the virtual Oppenheimer healthcare conference on February 26, 2026 at 8:00 am ET and making the webcast available for 90 days. Set against a stock price of $1.51, well below the $8.248 52-week high, and past negative reactions to clinical and earnings updates, investors may focus on future nebokitug milestones, cash runway disclosures, and additional data presentations as key catalysts.

Key Figures

Conference date: February 26, 2026 Presentation time: 8:00 am ET Webcast availability: 90 days +1 more

Conference date

February 26, 2026

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Presentation time

8:00 am ET

Scheduled webcast start time on conference date

Webcast availability

90 days

Length of time replay remains on Chemomab investor site

Conference edition

36th

Oppenheimer Annual Healthcare Life Sciences Conference

Historical Context

5 past events · Latest: Dec 02

5 events

1. Dec 02

   Phase 2 data

   24h Move

   -3.4%

   Publication of nebokitug Phase 2 SPRING PSC results in major journal.

2. Nov 24

   Investor conference

   24h Move

   -4.7%

   Participation at Oppenheimer rare disease summit with investor meetings.

3. Nov 20

   Quarterly earnings

   24h Move

   -10.0%

   Q3 2025 results and regulatory alignment on single Phase 3 trial.

4. Nov 06

   Clinical presentations

   24h Move

   -3.4%

   AASLD liver meeting posters with favorable nebokitug OLE data.

5. Aug 21

   Investor conference

   24h Move

   -3.6%

   Announcement of H.C. Wainwright global investment conference participation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fibro-inflammatory

1 terms

fibro-inflammatory medical

"developing innovative therapeutics for fibro-inflammatory diseases with high unmet need"

A fibro-inflammatory condition combines ongoing inflammation with the buildup of scar-like tissue, causing organs or tissues to thicken, stiffen or lose function — think of a cut that keeps getting irritated while scar tissue keeps piling up. For investors, the label signals chronic, progressive disease that often requires long-term treatment, shapes clinical trial and regulatory needs, and can create sustained demand (and cost) for therapies and medical services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36^th Annual Healthcare Life Sciences Conference on February 26, 2026. The corporate presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days.

Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date:	February 26, 2026
Time:	8:00 am ET
Venue:	Virtual
Format:	Webcast presentation
Webcast Link:	https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/L6ucs8kK8ypQvdjEBzP3QH
Information:	opcoconferences@opco.com

About Chemomab Therapeutics Ltd.                                                                                                                        .
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from five clinical trials of nebokitug. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), Chemomab and the FDA have aligned on the design of a nebokitug Phase 3 registration trial in patients with PSC. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has received FDA and EMA Orphan Drug designations and has an open U.S. IND. For more information, visit: chemomab.com.

Contacts:

Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Chemomab (CMMB) present at the Oppenheimer conference on February 26, 2026?

Chemomab will present on February 26, 2026 at 8:00 am ET. According to Chemomab, the session is a virtual webcast with management delivering a corporate presentation and participating in one-on-one investor meetings.

How can investors watch the Chemomab (CMMB) webcast from the Oppenheimer conference?

Investors can watch the live webcast via the event link or the company investor relations site. According to Chemomab, the corporate presentation will be webcast live and posted on its investor relations page for 90 days.

Will Chemomab (CMMB) management be available for meetings at the Oppenheimer conference?

Yes. Chemomab management will hold one-on-one investor meetings in addition to the presentation. According to Chemomab, CEO Dr. Adi Mor and other senior executives will participate in investor meetings during the virtual conference.

Where can I find the Chemomab (CMMB) presentation after the Oppenheimer conference?

The presentation will be archived for 90 days on Chemomab's investor relations website. According to Chemomab, the corporate webcast will remain available at the investor relations section for a 90-day viewing window after the live event.

What is the format and access information for Chemomab's (CMMB) Oppenheimer presentation?

The format is a virtual webcast presentation accessible via the event webcast link. According to Chemomab, the event is virtual on February 26, 2026 at 8:00 am ET and includes a live corporate presentation and investor meetings.

Who from Chemomab (CMMB) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?

CEO Dr. Adi Mor and senior management will present and meet investors. According to Chemomab, the company's CEO and other senior team members will deliver the corporate presentation and take part in one-on-one meetings.